Cantor Fitzgerald Brokers Cut Earnings Estimates for IDYA

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for IDEAYA Biosciences in a report released on Thursday, May 8th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($2.62) per share for the year, down from their previous forecast of ($2.35). The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($3.07) per share.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same period in the prior year, the firm posted ($0.53) EPS.

Several other research firms have also recently issued reports on IDYA. Stephens reiterated an "overweight" rating and set a $50.00 target price on shares of IDEAYA Biosciences in a research report on Friday, February 14th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a report on Wednesday, January 15th. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IDEAYA Biosciences presently has an average rating of "Moderate Buy" and a consensus price target of $54.27.

IDEAYA Biosciences Trading Down 2.0%

Shares of IDEAYA Biosciences stock traded down $0.35 on Monday, reaching $17.10. 1,004,375 shares of the stock were exchanged, compared to its average volume of 993,643. The firm has a market capitalization of $1.50 billion, a PE ratio of -5.18 and a beta of 0.26. IDEAYA Biosciences has a 1-year low of $13.45 and a 1-year high of $44.42. The business has a fifty day moving average price of $17.69 and a two-hundred day moving average price of $22.48.

Institutional Trading of IDEAYA Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC increased its stake in shares of IDEAYA Biosciences by 188.8% during the 3rd quarter. Barclays PLC now owns 181,170 shares of the company's stock worth $5,739,000 after purchasing an additional 118,438 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in IDEAYA Biosciences by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 79,780 shares of the company's stock valued at $2,527,000 after buying an additional 12,029 shares during the last quarter. SG Americas Securities LLC increased its position in IDEAYA Biosciences by 444.2% during the fourth quarter. SG Americas Securities LLC now owns 18,486 shares of the company's stock worth $475,000 after buying an additional 15,089 shares in the last quarter. KBC Group NV raised its holdings in shares of IDEAYA Biosciences by 84.6% in the fourth quarter. KBC Group NV now owns 4,197 shares of the company's stock worth $108,000 after acquiring an additional 1,923 shares during the last quarter. Finally, R Squared Ltd acquired a new position in shares of IDEAYA Biosciences in the fourth quarter worth $35,000. Hedge funds and other institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.